{
    "clinical_study": {
        "@rank": "100737", 
        "arm_group": [
            {
                "arm_group_label": "prefilled pen then prefilled syringe", 
                "arm_group_type": "Other", 
                "description": "weekly methotrexate injection with a prefilled pen during 3 weeks and subsequently with the prefilled syringe the last 3 weeks"
            }, 
            {
                "arm_group_label": "prefilled syringe then prefilled pen", 
                "arm_group_type": "Other", 
                "description": "weekly methotrexate injection with a prefilled syringe during 3 weeks and subsequently with the prefilled pen the last 3 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to assess the number of patients preferring the\n      methotrexate pre-filled pen to the methotrexate pre-filled syringe after 6 weeks of\n      treatment based on a questionnaire"
        }, 
        "brief_title": "Preference Methotrexate (MTX) Pre-filled Syringe Versus Pre-filled Pen in Rheumatoid Arthritis (RA)", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent\n\n          -  Age between 18 and 75 years\n\n          -  Rheumatoid arthritis according to the American College of Rheumatology (ACR) criteria\n             1987 or ACR/European Liga Against Rheumatology (EULAR)2010\n\n          -  Disease activity score (DAS) 28 > 2.6\n\n        Main Exclusion Criteria:\n\n          -  Prior or other current subcutaneous treatment with self-injection\n\n          -  Prior or concomitant treatment with biologics\n\n          -  Contraindications to MTX treatment\n\n          -  History or diagnosis of a dermatological disease at the  injection site\n\n          -  Women with child-bearing potential who do not use a highly effective method of\n             contraception or men who have a partner with child-bearing potential and do not use a\n             contraception during the study and at least 6 months thereafter."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01793259", 
            "org_study_id": "MC-MTX.11/RA"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "prefilled pen then prefilled syringe", 
                    "prefilled syringe then prefilled pen"
                ], 
                "intervention_name": "methotrexate prefilled pen", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "prefilled pen then prefilled syringe", 
                    "prefilled syringe then prefilled pen"
                ], 
                "intervention_name": "methotrexate prefilled syringe", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Methotrexate"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 12, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bad Nauheim", 
                    "country": "Germany", 
                    "zip": "61231"
                }, 
                "name": "Kerckhoff Clinic"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label, Randomized, Two-period Cross-over Study of Repeated Subcutaneous Injections of Methotrexate 50mg/ml Solution Either by a Pre-filled Syringe (Reference) or by a Disposable Pre-filled Pen (Test) to Assess Patient's Preference and Self-injection Experience and to Compare the Local Tolerability in Patients With Active Rheumatoid Arthritis", 
        "overall_official": {
            "affiliation": "Kerckoff clinic, Bad Nauheim, Germany", 
            "last_name": "Ulf M\u00fcller-Ladner, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "number of patients preferring the MTX pre-filled pen to the pre-filled syringe", 
            "safety_issue": "No", 
            "time_frame": "after 6 weeks of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01793259"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "medac GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "medac GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}